CD200 and neoplasm: The expression levels of immune checkpoints, including BTLA, VTCN1, CD276, PDCD1, CD160, NRP2, and CD200, as well as the tumor-associated fibroblast marker FAP, were found to be higher in the high-risk group (Figure 3G).